CYTEK(US:CTKB) ZACKS·2025-11-06 01:11Core Insights - Cytek Biosciences, Inc. reported a quarterly loss of $0.01 per share, matching the Zacks Consensus Estimate, but representing a 200% earnings surprise compared to the previous year's earnings of $0.01 per share [1] - The company generated revenues of $52.29 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 1.7% and showing a year-over-year increase from $51.5 million [2] - Cytek Biosciences shares have declined approximately 39.8% year-to-date, contrasting with the S&P 500's gain of 15.1% [3] Earnings Outlook - The future performance of Cytek Biosciences' stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is $0.04 on revenues of $57.63 million, and for the current fiscal year, it is also $0.04 on revenues of $196.08 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Cytek Biosciences belongs, is currently ranked in the top 40% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]